Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

RDN for CKD and Uncontrolled Hypertension Trial

16 de novembro de 2026 atualizado por: Beijing Anzhen Hospital

Effect and Safety of Renal Denervation in Uncontrolled Hypertension and Chronic Kidney Disease: A Randomized, Sham-control, Blinded, Clinical Trial

Prospective, Multi-Center, Randomized, Parallel-Controlled, Uptake clinical trial to evaluate the efficacy and safety of renal denervation in patients with uncontrolled hypertension and chronic kidney disease.

Visão geral do estudo

Status

Recrutamento

Condições

Intervenção / Tratamento

Descrição detalhada

This Prospective, Multi-Center, Randomized, parallel-controlled uptake clinical trial aims to evaluate the efficacy and safety for renal denervation in patients with uncontrolled hypertension and chronic kidney disease, and to provide clinical evidence supporting the expansion of indications.

Tipo de estudo

Intervencional

Inscrição (Estimado)

248

Estágio

  • Não aplicável

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Contato de estudo

  • Nome: Luyun Fan
  • Número de telefone: +86-13522601484
  • E-mail: katevan@163.com

Estude backup de contato

Locais de estudo

      • Beijing, China, 101118
        • Recrutamento
        • Beijing Anzhen Hospital
        • Contato:

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

18 anos a 65 anos (Adulto, Adulto mais velho)

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Tudo

Descrição

Inclusion Criteria:

  1. Male or female, aged 18 to 65 years, inclusive, at the time of consent;
  2. Hypertensive subjects who have been taking 2 types of standardized antihypertensive drugs continuously and stably for at least 4 weeks, with office systolic blood pressure still ≥150 mmHg and <180 mmHg, and 24-hour ambulatory mean systolic blood pressure (24h SBP) ≥135 mmHg and <170 mmHg; or who have been taking ≥3 types of standardized antihypertensive drugs continuously and stably for at least 4 weeks, with office systolic blood pressure ≥140 mmHg and <180 mmHg, and 24h SBP ≥130 mmHg and <170 mmHg;
  3. Estimated glomerular filtration rate (eGFR) ≥20 mL/min/1.73m² and <60 mL/min/1.73m²;
  4. The presence or absence of accessory renal arteries is acceptable;
  5. The subject or his/her legal representative fully understands the content of the informed consent form for this trial and voluntarily signs the written informed consent form.

Exclusion Criteria:

  1. Pregnant or breastfeeding, or planning pregnancy during the study.
  2. Renal artery anatomy unsuitable for ablation (e.g., ≥50% stenosis, renal artery aneurysm, malformation, renal artery diameter <3 mm, or treatable segment length <20 mm).
  3. Subjects with a solitary kidney, prior renal transplantation, or requiring dialysis.
  4. Prior renal artery intervention or prior renal denervation.
  5. Other secondary hypertension not related to kidney disease (such as primary aldosteronism, pheochromocytoma/paraganglioma, Cushing's syndrome, thyroid disease, aortic coarctation, monogenic hypertension, renovascular hypertension, etc.).
  6. Allergic to contrast agents.
  7. Major surgery or trauma within 1 month before enrollment; acute coronary syndrome within 6 months; or planned surgery or cardiovascular interventional therapy within the next 6 months.
  8. Orthostatic hypotension.
  9. Type 1 diabetes mellitus.
  10. Primary pulmonary arterial hypertension.
  11. History of bleeding diathesis and haematological disorders or coagulopathy
  12. History of thromboembolic event within 6 months.
  13. History of stroke or transient ischemic attack (TIA) within 6 months.
  14. Severe peripheral arterial disease or unstable abdominal aortic aneurysm.
  15. Severe valvular heart disease or anticipated need for surgical valve replacement during the study period.
  16. NYHA Class III/IV heart failure at screening or hospitalization for exacerbation of chronic heart failure within the past six months.
  17. History of ventricular fibrillation, polymorphic ventricular tachycardia within six months, or prior implantation of an implantable cardioverter-defibrillator (ICD) or pacemaker.
  18. Acute kidney injury (AKI) within 4 weeks before enrollment or acute kidney disease ,AKI: ≥50% increase in serum creatinine within 7 days, or absolute increase ≥0.3 mg/dL (≥26.5 μmol/L) within 48 hours, or oliguria (<0.5 mL·kg-¹·h-¹ for ≥6 hours).
  19. Severe hepatic dysfunction.
  20. Concomitant severe diseases that may interfere with study participation or affect survival, such as malignancy or AIDS.
  21. Known drug or alcohol dependence, difficulty understanding the study protocol, inability or unwillingness to comply with follow-up requirements.
  22. Current or planned participation in other clinical trials of drugs or medical devices (post-marketing registry studies permitted).
  23. Acute or severe systemic infection.
  24. Other conditions deemed unsuitable for participation by the investigator.

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Tratamento
  • Alocação: Randomizado
  • Modelo Intervencional: Atribuição Paralela
  • Mascaramento: Solteiro

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Experimental: Renal Denervation (RDN)

Participants receive percutaneous renal sympathetic denervation under digital subtraction angiography (DSA) guidance using a ultra-guiding radiofrequency denervation catheter. All participants receive a standardized antihypertensive regimen for ≥4 weeks before the procedure and thereafter per protocol. Follow-up visits occur at 7 days or before discharge, and at 1, 3, 6, 12 months.

DSA-guided percutaneous renal sympathetic denervation using a RF renal denervation system

Outros nomes:
  • Denervação Renal
Comparador Falso: Parallel control with sham operation

Participants undergo a sham procedure: femoral artery puncture and selective renal angiography under DSA guidance are performed. The RF generator is connected to a dummy load, and activation sounds are emitted, but no energy is delivered. Participants remain on the procedure table for at least 35 minutes before sheath removal. Background standardized antihypertensive therapy is provided for ≥4 weeks pre-procedure and continued per protocol. Follow-up visits occur at 7 days or before discharge, and at 1, 3, 6, and 12 months.

Sham procedure including femoral artery puncture and selective renal angiography; the radiofrequency generator is connected to a dummy load and produces activation sounds, but no energy is delivered. Minimum table time before sheath removal is 35 minutes.

Outros nomes:
  • Angiografia Renal

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Change from Baseline in 24-hour Ambulatory Systolic Blood Pressure at Month 6 (ABPM)
Prazo: Baseline to Month 6 post-procedure

24-hour mean systolic BP measured by validated ambulatory BP monitoring; change is Month 6 minus Baseline

Baseline to Month 6 post-procedure

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Change from Baseline in 24-hour Ambulatory Diastolic Blood Pressure at Month 6 (ABPM)
Prazo: Baseline to Month 6 post-procedure

24-hour mean systolic BP measured by validated ambulatory BP monitoring

Baseline to Month 6 post-procedure
Change from Baseline in Office Blood Pressure (including both systolic and diastolic BP)
Prazo: Baseline to Months 1, 3, 6 and 12 post-procedure

measured by validated office blood pressure monitoring

Baseline to Months 1, 3, 6 and 12 post-procedure
Change from Baseline in 24-hour Ambulatory Systolic Blood Pressure (including both systolic and diastolic BP)
Prazo: Baseline to Months 1, 3, and 12 post-procedure

24-hour mean systolic BP measured by validated ambulatory BP monitoring

Baseline to Months 1, 3, and 12 post-procedure
Change from Baseline in Daytime and Nighttime Ambulatory Systolic Blood Pressure (ABPM)
Prazo: Baseline to Months 1, 3, 6, and 12 post-procedure

24-hour mean systolic BP measured in Daytime and Nighttime by validated ambulatory BP monitoring

Baseline to Months 1, 3, 6, and 12 post-procedure
Percentage of Participants with 24-hour Ambulatory Systolic BP <130 mmHg
Prazo: Months 1, 3, 6, and 12 post-procedure

24-hour mean systolic BP measured by validated ambulatory BP monitoring

Months 1, 3, 6, and 12 post-procedure
Percentage of subjects with office systolic BP within the target ranges (<140 mmHg and <130 mmHg)
Prazo: Months 6 and 12 post-procedure

measured by validated office blood pressure monitoring

Months 6 and 12 post-procedure
Responder Rate: ≥5 mmHg Reduction in office Systolic BP
Prazo: Months 6 and 12 post-procedure

Proportion of participants with a reduction ≥5 mmHg from baseline in office BP

Months 6 and 12 post-procedure
Change from Baseline in Antihypertensive Medication Use
Prazo: Months 1, 3, 6 and 12 post-procedure

Change in the number of concurrently prescribed antihypertensive agents

Months 1, 3, 6 and 12 post-procedure
Change from Baseline in serum creatinine levels
Prazo: Months 1, 3, 6 and 12 post-procedure

Change in postoperative serum creatinine levels relative to baseline

Months 1, 3, 6 and 12 post-procedure
Changes from Baseline in glomerular filtration rate
Prazo: Months 1, 3, 6 and 12 post-procedure

Changes in glomerular filtration rate relative to baseline

Months 1, 3, 6 and 12 post-procedure
Changes from Baseline in the urine microalbumin-to-creatinine ratio
Prazo: Months 1, 3, 6 and 12 post-procedure

Changes in the urine microalbumin-to-creatinine ratio relative to baseline

Months 1, 3, 6 and 12 post-procedure
Change from Baseline in Heart Rate (by ECG)
Prazo: Months 1, 3, 6 and 12 post-procedure

Resting heart rate measured by standard 12-lead ECG; change is Follow-up minus Baseline

Months 1, 3, 6 and 12 post-procedure
Change from Baseline in left ventricular ejection fraction (LVEF) (by Echocardiography)
Prazo: Months 12 post-procedure

by Echocardiography

Months 12 post-procedure
Change from Baseline in left ventricular mass index
Prazo: Months 12 post-procedure

by Echocardiography

Months 12 post-procedure

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Patrocinador

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Real)

8 de dezembro de 2025

Conclusão Primária (Estimado)

31 de outubro de 2027

Conclusão do estudo (Estimado)

30 de abril de 2028

Datas de inscrição no estudo

Enviado pela primeira vez

26 de outubro de 2026

Enviado pela primeira vez que atendeu aos critérios de CQ

16 de novembro de 2026

Primeira postagem (Real)

18 de novembro de 2026

Atualizações de registro de estudo

Última Atualização Postada (Real)

18 de novembro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

16 de novembro de 2026

Última verificação

1 de novembro de 2026

Mais Informações

Termos relacionados a este estudo

Outros números de identificação do estudo

  • BRWEP2024W012060105

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

NÃO

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Não

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .